AngioSoma Advances With Two New Product Offerings

Houston, TX, Oct. 18, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma (SOAN), a leading pharmaceutical research and development company, announces that trademarks have been awarded for two new products, AngioMagic™ and Somniac PM™.  AngioMagic™ is a dietary supplement that Improves health and wellbeing.   Somniac PM™ is a sleep aid designed to provide a more restful and beneficial sleep experience.

“We are excited about moving AngioMagic™ and Somniac PM™ into the next phase of development,” says Alex Blankenship, president of AngioSoma. “AngioSoma is committed to creating the best solutions for common health problems.  This announcement brings two new company properties into focus as another example of our innovative approach to product research and development as we prepare to bring them to market.”

AngioSoma has over twenty years of research and development experience, from expired patent technology to existing patents, the company continues to expand Its product offerings and company value for shareholders and patients across the globe.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (https:// angiosoma.com), a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our Somaceuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.